R&D Pipeline

An Overview of Bausch's 230 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress

26 July 2023
3 min read

Bausch Health Cos., Inc., formerly known as Valeant Pharmaceuticals International, is a pharmaceutical company founded in 1959 and headquartered in Quebec, Canada. The company operates in the field of biomedicine and has a diverse portfolio of drugs targeting various therapeutic areas.

According to the distribution of therapeutic areas, Bausch Health Cos., Inc. has a significant focus on skin and musculoskeletal diseases, with 36 drugs in its portfolio. Other diseases, nervous system diseases, infectious diseases, and eye diseases are also areas of emphasis for the company, with drug counts of 31, 29, 25, and 23 respectively. Immune system diseases, neoplasms, and digestive system disorders are also areas where Bausch Health Cos., Inc. has a notable presence.

图形用户界面, 应用程序

描述已自动生成

In terms of the most frequently developed targets, Bausch Health Cos., Inc. has focused on several key targets. The glucocorticoid receptor (GR) is the most frequently targeted, with 4 drugs developed. Other targets include fungal CYP51A1, GABAA receptor, GR + PLA2G4A, COX, mAChRs, 50S subunit, GC-C, and PTGFR, among others. These targets represent a range of therapeutic areas and indicate the company's commitment to addressing various diseases and conditions.

Looking at the pipeline for Bausch Health Cos., Inc. till 2023-07-26, it is evident that the company has a significant number of drugs in advanced stages of development. The pipeline includes drugs in preclinical, Phase 1, Phase 2, Phase 3, NDA/BLA, and approved stages. Notably, there are 78 drugs that have already received approval, indicating the company's success in bringing new treatments to market.

In terms of the distribution of drugs across different phases, the majority of drugs are in the approved stage, followed by the other category, which likely includes drugs that are in earlier stages of development or have not yet progressed to clinical trials. Among the clinical stages, Phase 2 has the highest number of drugs, with 6 in development, followed by Phase 3 with 4 drugs. The presence of drugs in Phase 1 indicates ongoing research and development efforts by Bausch Health Cos., Inc.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The information provided gives an overview of Bausch Health Cos., Inc.'s activities in the pharmaceutical industry. The company has a diverse portfolio of drugs targeting various therapeutic areas, with a particular focus on skin and musculoskeletal diseases, other diseases, nervous system diseases, and infectious diseases. The most frequently developed targets include the glucocorticoid receptor, fungal CYP51A1, and GABAA receptor, among others.

The pipeline for Bausch Health Cos., Inc. indicates a significant number of drugs in advanced stages of development, with a substantial number already approved. This suggests that the company has a strong track record in bringing new treatments to market. The presence of drugs in earlier stages of development indicates ongoing research and development efforts by the company.

Overall, Bausch Health Cos., Inc. is a pharmaceutical company with a diverse portfolio of drugs targeting various therapeutic areas. The company's focus on research and development is evident from its pipeline, which includes drugs in different stages of development. With its long history in the industry and a strong presence in the market, Bausch Health Cos., Inc. continues to contribute to the advancement of biomedicine and the treatment of various diseases and conditions.

图形用户界面, 文本, 应用程序

描述已自动生成

Anaprazole Sodium——Next Generation Proton Pump Inhibitors
Drug Insights
2 min read
Anaprazole Sodium——Next Generation Proton Pump Inhibitors
26 July 2023
Anaprazole Sodium is a small molecule proton pump inhibitor (PPI) developed by Beijing Sihuan Pharmaceutical Co. Ltd., approved by NMPA on June 21, 2023, for the treatment of duodenal ulcers.
Read →
Targeting the Siglec-9 Immune Checkpoint: A New Approach to Enhance Immunotherapy
Advanced Tech.
5 min read
Targeting the Siglec-9 Immune Checkpoint: A New Approach to Enhance Immunotherapy
25 July 2023
The studies discussed here provide a foundation for the development of novel approaches to improve the efficacy of cancer immunotherapy.
Read →
Delandistrogene moxeparvovec - The first DMD Gene Therapy
Drug Insights
3 min read
Delandistrogene moxeparvovec - The first DMD Gene Therapy
24 July 2023
Delandistrogen moxeparvovec, also known as SRP-9001, trade name ELEVIDYS, is a kind of Adeno-associated virus gene therapy targeting micro dystrophin.
Read →
An Overview of Sumitomo Dainippon's 304 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
R&D Pipeline
4 min read
An Overview of Sumitomo Dainippon's 304 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
24 July 2023
Sumitomo Pharma Co., Ltd. is a pharmaceutical organization based in Osaka-fu, Japan. It was founded in 1984 and has since been actively involved in the field of biomedicine.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.